ポスト
In a phase 2 trial in patients with metabolic dysfunction–associated steatohepatitis and moderate or severe fibrosis, tirzepatide was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. https://t.co/YBoR7D9n4h #EASLCongress https://t.co/ZlLOxvrtOG
メニューを開く